Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ: ANAB )

17.71 +0.17 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 844,169
Open 17.39
Bid (Size) 17.70 (3)
Ask (Size) 18.50 (22)
Prev. Close 17.54
Today's Range 16.77 - 18.50
52wk Range 12.21 - 41.31
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Where AnaptysBio Stands With Analysts
Via Benzinga
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire

Performance

YTD
+32.56%
+32.56%
1 Month
+36.23%
+36.23%
3 Month
+14.18%
+14.18%
6 Month
-50.26%
-50.26%
1 Year
-32.04%
-32.04%

More News

Read More
Anaptys Announces Participation in March Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Analyst Expectations For AnaptysBio's Future
Via Benzinga
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Key Takeaways From AnaptysBio Analyst Ratings
Via Benzinga
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
Via Investor's Business Daily
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
From AnaptysBio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
Via Benzinga
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in November and December Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.